All Posts Tagged With: "GENZ"
(ISIS) Isis Pharmaceuticals Analyst Retains Neutral on Shares
We recently reiterated a Neutral recommendation (Zacks #3 Rank – short-term “Hold” rating) on Isis Pharmaceuticals (ISIS). Isis Pharma is a drug discovery and development company that focuses on the development of products using ribonucleic acid (RNA)-based technologies,...
9Apr2011 | vitalstocks | 0 comments | Continued(ACXM) Company News for March 31, 2011 – Corporate Summary
• According to a report from Bloomberg, Valeant Pharmaceuticals (NYSE:VRX) made a hostile bid to acquire Cephalon (NASDAQ:CEPH) for about $73 a share in cash or about $5.7 billion, after earlier bids were rejected • Standard & Poor’s said the world’s biggest asset...
31Mar2011 | vitalstocks | 0 comments | Continued(VRX) Valeant Pharmaceuticals International’s Sales Benefit Post Merger
Valeant Pharmaceuticals International‘s (VRX) fourth quarter 2010 earnings of 46 cents per share missed the Zacks Consensus Estimate by a cent and was 45.2% below the year-ago earnings of 84 cents per share. Revenues for the quarter increased 102.7% year over year to $514.6...
7Mar2011 | vitalstocks | 0 comments | Continued(PLX) Protalix BioTherapeutics Sees FDA Setback for Gaucher Drug
Protalix BioTherapeutics, Inc. (PLX) was dealt a huge blow recently with the US Food and Drug Administration (FDA) issuing a complete response letter (CRL) for the company’s Gaucher disease candidate, taliglucerase alfa. FDA Requests Additional Information The FDA asked the...
4Mar2011 | vitalstocks | 0 comments | Continued(JNJ) Pharmaceutical Industry Outlook – March 2011 – Industry Outlook
The pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance...
2Mar2011 | vitalstocks | 0 comments | Continued(AA) Stock Market News for February 22, 2011 – Market News
The markets registered their third straight week of gains as the indices closed with multi-year highs on Friday. China’s measures to curb inflation and continuing tension in the Middle East failed to cause any damage to the markets as energy stocks led the indices higher. On...
22Feb2011 | vitalstocks | 0 comments | Continued(GENZ) Genzyme Corporation Results Eclipsed by Sanofi-Aventis Deal
Genzyme Corporation (GENZ) reported fourth quarter earnings of 71 cents per share (excluding one-time items but including the impact of stock-based compensation expense), a couple of cents below the Zacks Consensus Estimate, but significantly above the year-earlier earnings of...
18Feb2011 | vitalstocks | 0 comments | Continued(ANF) Stock Market News for February 17, 2011 – Market News
Markets ended in the green after optimistic news about the economy from the Fed lifted the mood of investors. Earlier in the day, news of strong earnings and deals sent the markets higher. The Dow Jones Industrial Average rose 0.5% to 12,228.17. 23 out of 30 stocks of the blue...
17Feb2011 | vitalstocks | 0 comments | Continued(SNY) Sanofi-Aventis Earnings Meet Expectations – Decrease From Year-Ago
Sanofi-Aventis (SNY) reported fourth quarter earnings of 96 cents per American Depository Share (ADS), a penny above the Zacks Consensus Estimate but below the year-ago earnings of $1.04. Full year earnings came in at $4.69 per ADS, in line with the Zacks Consensus Estimate and...
11Feb2011 | vitalstocks | 0 comments | Continued(PFE) Pfizer and Protalix BioTherapeutics Seek EU Approval
Pfizer (PFE) and its partner Protalix BioTherapeutics Inc. (PLX) recently announced that they have submitted the Marketing Authorization Application (MAA) for their Gaucher disease candidate in the EU. The companies are seeking marketing approval for Uplyso (taliglucerase alfa)...
21Dec2010 | vitalstocks | 0 comments | Continued(GENZ) Genzyme Corporation is in Deal for Sale of Diagnostic Business
Genzyme Corporation (GENZ) recently announced that it has entered into an agreement with Japanese company, Sekisui Chemical Co., Ltd. for the sale of its diagnostic products business. Sekisui will acquire Genzyme’s diagnostic products business for $265 million cash. The diagnostics...
6Dec2010 | vitalstocks | 0 comments | Continued(ISIS) Isis Pharmaceuticals Reports Loss Widens
Isis Pharmaceuticals Inc. (ISIS) reported a net loss of 13 cents per share in the third quarter 2010, wider than the year-ago loss of 12 cents. The higher loss was mainly due to higher operating expenses. However, third quarter loss was narrower than the Zacks Consensus Estimate...
15Nov2010 | vitalstocks | 0 comments | Continued(JNJ) Pharma & Biotech Industry Outlook – November 2010 – Industry Outlook
With 2010 coming to an end, the pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance...
15Nov2010 | vitalstocks | 0 comments | Continued(SNY) Sanofi-Aventis Presents Encouraging Data on MS Drug
French pharmaceutical company, Sanofi-Aventis (SNY) recently presented encouraging results on its multiple sclerosis (MS) candidate, teriflunomide. Results from a phase III randomized, double-blind, placebo-controlled study (TEMSO) showed that teriflunomide helped reduce annualized...
18Oct2010 | vitalstocks | 0 comments | Continued(SNY) Sanofi-Aventis Makes Hostile Bid for Genzyme
French pharma giant Sanofi-Aventis (SNY) recently went hostile with its bid to acquire biotech company Genzyme Corporation (GENZ). Sanofi has launched a tender offer for all outstanding shares of Genzyme – the offer is scheduled to expire on Dec 10. Sanofi’s offer price stands...
11Oct2010 | vitalstocks | 0 comments | Continued(CTIC) Cell Therapeutics Analyst Cuts Shares to Underperform
We are downgrading Cell Therapeutics, Inc. (CTIC) to Underperform from Neutral with a price target of $0.25 primarily due to the uncertainty surrounding the US approval of its lead candidate, pixantrone. Pixantrone (proposed trade name: Pixuvri), is currently under development...
7Oct2010 | vitalstocks | 0 comments | Continued(GENZ) Genzyme Rejects Sanofi-Aventis’ Aquisition Offer
Genzyme Corp. (GENZ) recently rejected Sanofi-Aventis’ (SNY) offer to acquire the company for $69 per share. Earlier in the day, Sanofi had announced its non-binding proposal to Genzyme with the all-cash transaction being valued at $18.5 billion. However, Genzyme’s board...
16Sep2010 | vitalstocks | 0 comments | Continued(BAC) Company News for August 31, 2010 – Corporate Summary
• Some private investors are reportedly considering an offer for Saks (NYSE:SKS). The offer values the luxury retailer at $1.7 billion, or $11 per share • Citigroup (NYSE:C) noted Sanofi-Aventis (NYSE:SNY) may bid up to $74-$77 per share for Genzyme (NASDAQ:GENZ) • Deere...
31Aug2010 | vitalstocks | 0 comments | Continued(SHPGY) Shire Plc Earns European Approval for Vpriv
Recently, Shire Plc. (SHPGY) received a boost when the European Commission approved its Gaucher disease product Vpriv (velaglucerase alfa) for marketing in 30 European countries. The decision to approve the product does not come as a surprise as the drug’s approval for the...
28Aug2010 | vitalstocks | 0 comments | Continued(HPQ) Can $1.84 Trillion in Corporate Cash Save U.S. Economy?
by Marc Lichtenfeld, Advisory Panelist Wednesday, August 25, 2010: Issue #1331 Scan the headlines these days and a lengthy list of negatives will stare you in the face. Stubbornly high numbers of unemployed Americans. The gargantuan (and ever-increasing) budget deficit. And...
25Aug2010 | InvestmentU | 0 comments | Continued(CELG) Celgene Analyst Maintains Neutral Rating With $58 Target Price
We are maintaining our Neutral recommendation on Celgene Corporation (CELG) with a target price of $58. Celgene, founded in 1986 and headquartered in Summit, NJ, focuses on the discovery, development and commercialization of drugs in the areas of cancer and immune/inflammatory...
22Aug2010 | vitalstocks | 0 comments | Continued(CELG) Celgene Analyst Maintains Neutral Recommendation
We are maintaining our Neutral recommendation on Celgene Corporation (CELG) with a target price of $58. Celgene, founded in 1986 and headquartered in Summit, NJ, focuses on the discovery, development and commercialization of drugs in the areas of cancer and immune/inflammatory...
18Aug2010 | vitalstocks | 0 comments | Continued(SHPGY) Shire plc Second Quarter 2010 Earnings Beat – Updates Outlook
Shire plc (SHPGY) posted earnings of $1.03 per American Depositary Share (ADS) during the second quarter of 2010, beating the Zacks Consensus Estimate of 88 cents and the year-ago earnings of 60 cents per ADS. Improved revenues accounted for the increased earnings. Revenues Quarterly...
10Aug2010 | vitalstocks | 0 comments | Continued(HSP) Hospira Second Quarter 2010 Earnings Preview
Hospira Inc. (HSP) is scheduled to report its second quarter 2010 results on Wednesday, July 28, before the opening bell. The Zacks Consensus Estimate for the quarter is earnings of 79 cents per share (with an upside of 2.53%), compared with earnings of 73 cents per share in...
2Aug2010 | vitalstocks | 0 comments | Continued(MRK) Pharma Merger Mania is Heating Up
by Marc Lichtenfeld, Healthcare Expert Wednesday, July 28, 2010: Issue #1311 In the cellphone world, it’s all about “apps.” In the oil and natural gas industries, it’s all about supplies. And in the healthcare sector, it’s all about pills. Lots and lots of pills. Blue...
31Jul2010 | InvestmentU | 0 comments | Continued(MRK) Big Pharma Has a Big Problem and Merger Mania is Heating Up
by Marc Lichtenfeld, Healthcare Expert Wednesday, July 28, 2010: Issue #1311 In the cellphone world, it’s all about “apps.” In the oil and natural gas industries, it’s all about supplies. And in the healthcare sector, it’s all about pills. Lots and lots of pills. Blue...
28Jul2010 | InvestmentU | 0 comments | Continued(ABT) Pharma and Biotech Industry Outlook – July 2010 – Analyst Interviews
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant...
26Jul2010 | vitalstocks | 0 comments | Continued(GENZ) Genzyme Second Quarter 2010 Earnings Miss by a Wide Margin
Genzyme Corporation (GENZ) reported second quarter earnings of 6 cents per share (excluding one-time items but including the impact of stock-based compensation expense), well below the Zacks Consensus Estimate of 36 cents and the year-earlier earnings of 64 cents. Excluding the...
21Jul2010 | vitalstocks | 0 comments | Continued(ABT) Pharma and Biotech Industry Outlook – July 2010 – Industry Outlook
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant...
20Jul2010 | vitalstocks | 0 comments | Continued(SHPGY) Shire plc Hears Good News From European Medicines Agency
Recently Shire plc (SHPGY) announced that its Gaucher disease product VPRIV (velaglucerase alfa) has received a favorable opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). The committee recommended the approval of the...
11Jul2010 | vitalstocks | 0 comments | Continued